- Home
- SQFT vs RNAZ Comparison
SQFT vs RNAZ Comparison
Compare SQFT & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- RNAZ
- Stock Information
- Founded
- SQFT 1999
- RNAZ 2016
- Country
- SQFT United States
- RNAZ United States
- Employees
- SQFT N/A
- RNAZ N/A
- Industry
- SQFT Real Estate Investment Trusts
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SQFT Real Estate
- RNAZ Health Care
- Exchange
- SQFT Nasdaq
- RNAZ Nasdaq
- Market Cap
- SQFT 8.1M
- RNAZ 7.2M
- IPO Year
- SQFT 2020
- RNAZ 2021
- Fundamental
- Price
- SQFT $0.61
- RNAZ $1.12
- Analyst Decision
- SQFT
- RNAZ Strong Buy
- Analyst Count
- SQFT 0
- RNAZ 1
- Target Price
- SQFT N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- SQFT 23.3K
- RNAZ 582.0K
- Earning Date
- SQFT 03-18-2025
- RNAZ 03-31-2025
- Dividend Yield
- SQFT N/A
- RNAZ N/A
- EPS Growth
- SQFT N/A
- RNAZ N/A
- EPS
- SQFT N/A
- RNAZ N/A
- Revenue
- SQFT $18,586,052.00
- RNAZ N/A
- Revenue This Year
- SQFT N/A
- RNAZ N/A
- Revenue Next Year
- SQFT N/A
- RNAZ N/A
- P/E Ratio
- SQFT N/A
- RNAZ N/A
- Revenue Growth
- SQFT 5.44
- RNAZ N/A
- 52 Week Low
- SQFT $0.47
- RNAZ $1.10
- 52 Week High
- SQFT $1.39
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- SQFT 40.86
- RNAZ 27.23
- Support Level
- SQFT $0.62
- RNAZ $1.73
- Resistance Level
- SQFT $0.65
- RNAZ $2.20
- Average True Range (ATR)
- SQFT 0.03
- RNAZ 0.91
- MACD
- SQFT 0.00
- RNAZ -0.52
- Stochastic Oscillator
- SQFT 14.29
- RNAZ 0.22
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.